SILVER SPRING, Md. and NEW YORK, July 30, 2026
The TSC Alliance and Apertura Gene Therapy have announced the successful completion of a preclinical pilot study evaluating an innovative adeno-associated virus (AAV) gene therapy approach designed for TSC1, marking another important milestone in the development of next-generation genetic medicines for tuberous sclerosis complex (TSC). The collaboration demonstrated encouraging early findings that support continued preclinical evaluation of both TSC1 and TSC2 gene therapy programs using Apertura’s proprietary TfR1 CapX™ capsid technology. The organizations plan to expand research toward IND-enabling studies and future clinical trials, with the TSC Alliance committing to raise $1.76 million over the next 18 months to accelerate gene therapy development. The announcement highlights growing momentum in the gene therapy field as researchers seek transformative treatments capable of addressing the underlying genetic causes of rare neurological diseases rather than simply managing symptoms.
Promising Preclinical Results Support Continued Gene Therapy Development
The completed preclinical pilot study evaluated an AAV-based gene therapy platform designed to deliver healthy copies of the TSC1 gene directly to affected tissues. The investigational approach utilizes TfR1 CapX™, Apertura Gene Therapy’s next-generation intravenously administered AAV capsid engineered to engage the human transferrin receptor 1 (hTfR1) and efficiently cross the blood-brain barrier (BBB). This innovative delivery platform is designed to achieve broad distribution throughout the brain, spinal cord, and other organs, addressing one of the most significant challenges in neurological gene therapy. According to the organizations, the encouraging preclinical findings support further studies to determine whether the approach can advance toward clinical testing. Researchers will continue evaluating both TSC1 and TSC2 programs while generating additional data required for regulatory development and future human clinical trials.
TfR1 CapX™ Technology Could Transform Rare Neurological Disease Treatment
A major strength of the collaboration lies in Apertura’s proprietary TfR1 CapX™ capsid, a second-generation AAV delivery platform specifically engineered for intravenous administration and enhanced central nervous system delivery. Unlike conventional AAV vectors, TfR1 CapX™ is designed to utilize the natural human transferrin receptor 1 transport pathway, enabling efficient delivery of therapeutic genes across the blood-brain barrier while achieving widespread tissue distribution. The technology builds upon earlier scientific advances and has already attracted licensing interest from multiple organizations developing genetic medicines. Apertura noted that several programs utilizing its next-generation capsids are expected to enter clinical trials within the next year, reflecting increasing confidence in advanced AAV delivery technologies. If future studies continue to demonstrate safety and effectiveness, the platform could significantly expand treatment possibilities for patients living with rare neurological and genetic disorders, including tuberous sclerosis complex.
Advertisement
Collaboration Aims to Accelerate Clinical Translation for TSC Patients
The partnership demonstrates a shared commitment to translating promising laboratory discoveries into meaningful therapies for patients affected by tuberous sclerosis complex, a rare genetic disorder characterized by non-cancerous tumors affecting the brain, kidneys, heart, lungs, skin, and other organs. Approximately 85% of individuals with TSC experience seizures, while many patients develop treatment-resistant epilepsy, highlighting the urgent need for innovative therapeutic approaches. The TSC Alliance has pledged to raise $1.76 million over the next 18 months to support additional gene therapy studies evaluating both TSC1 and TSC2, with the long-term goal of advancing the programs into IND-enabling studies and ultimately clinical trials. The organizations emphasized that continued collaboration between patient advocacy groups and biotechnology innovators is critical for accelerating research and delivering potentially life-changing treatments to patients living with rare genetic diseases.
Source: Apertura Gene Therapy press release
